Loading...
•
Apr 30
Cooper Q2 2025 Earnings Report
Cooper reported higher revenue and EPS in Q2 2025, driven by strong performances in both CooperVision and CooperSurgical segments.
Key Takeaways
Cooper posted $1.002 billion in revenue and $87.7 million in net income for Q2 2025, with solid growth in both vision and surgical segments, and an improvement in gross and operating margins.
Revenue grew 6% YoY to $1.002 billion, driven by both CooperVision and CooperSurgical segments.
GAAP EPS remained flat at $0.44, while non-GAAP EPS rose to $0.96.
Operating income increased to $184.8 million, with operating margin improving to 18%.
Free cash flow was $18.1 million after capital expenditures of $78.1 million.
Cooper
Cooper
Cooper Revenue by Segment
Cooper Revenue by Geographic Location
Revenue by Segment
Toric & Multifocal Revenue
CapyFin.comSphere & Other Revenue
CapyFin.comOffice & Surgical Revenue
CapyFin.comFertility Revenue
CapyFin.comRevenue by Geographic Location
Americas Revenue
CapyFin.comEMEA Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.com Forward Guidance
CooperCompanies maintained strong guidance for FY2025 with expected revenue between $4.107B–$4.146B and non-GAAP EPS between $4.05–$4.11.
Positive Outlook
- Expected total revenue for FY2025 raised to $4.107–$4.146 billion.
- CooperVision revenue projected at $2.759–$2.786 billion.
- CooperSurgical expected to contribute $1.347–$1.359 billion.
- Non-GAAP EPS guidance of $4.05–$4.11 confirmed.
- Strong performance expected from daily silicone hydrogel lenses and surgical portfolio.
Challenges Ahead
- Guidance excludes potential acquisition-related charges.
- Non-GAAP EPS excludes restructuring and integration costs.
- Macroeconomic conditions may impact global operations.
- Foreign exchange volatility remains a concern.
- Regulatory costs and compliance remain elevated in Europe.
Revenue & Expenses
Visualization of income flow from segment revenue to net income